Sarcoma
Welcome,         Profile    Billing    Logout  
 504 Companies   302 Products   302 Products   167 Mechanisms of Action   1357 Trials   122306 News 


«12345678910111213...15251526»
  • ||||||||||  imatinib / Generic mfg.
    Journal, Stroma:  Adjuvant imatinib in high-risk resected gastrointestinal stromal tumors: Merely delaying the inevitable? (Pubmed Central) -  Jun 26, 2024   
    Treatment with adjuvant imatinib delays, but does not clearly impact ultimate recurrence, TTIR, or OS, suggesting many patients with high-risk GIST may receive adjuvant imatinib unnecessarily. Additional studies are needed to establish the benefit of adjuvant therapy versus initiating therapy at first radiographic recurrence.
  • ||||||||||  Journal:  Myc upregulates Ggct, ?-glutamylcyclotransferase to promote development of p53-deficient osteosarcoma. (Pubmed Central) -  Jun 26, 2024   
    Myc upregulates Ggct directly by binding to the Ggct promoter, and deletion of a Myc binding site therein by genome editing attenuated the tumorigenic potential of p53-deficient OS cells. Taken together, these results show a rationale that GGCT is widely upregulated in cancer cells and solidify its suitability as a target for anticancer drugs.
  • ||||||||||  Review, Journal:  Ferroptosis defense mechanisms: The future and hope for treating osteosarcoma. (Pubmed Central) -  Jun 26, 2024   
    In this paper, we summarize how, through the three major defense systems of ferroptosis, not only can substances from traditional Chinese medicine, antitumor drugs, and nano-drug carriers induce ferroptosis in OS cells, but they can also be combined with immunotherapy, differentiation therapy, and other treatment modalities to significantly enhance chemotherapy sensitivity and inhibit tumor growth. Thus, ferroptosis holds great potential in treating OS, offering more choices and possibilities for future clinical interventions.
  • ||||||||||  Review, Journal:  The role of N?-terminal acetylation in protein conformation. (Pubmed Central) -  Jun 26, 2024   
    In this review, we zoom in on one possible functional consequence of N?-terminal protein acetylation; its effect on protein folding. Using selected examples of proteins associated with human diseases such as alpha-synuclein and huntingtin, here, we discuss the sometimes contradictory findings of the effects of N?-terminal protein acetylation on protein (mis)folding and aggregation.
  • ||||||||||  Journal:  A case of angiosarcoma of the scalp with cardiac tamponade and hemothorax. (Pubmed Central) -  Jun 26, 2024   
    Using selected examples of proteins associated with human diseases such as alpha-synuclein and huntingtin, here, we discuss the sometimes contradictory findings of the effects of N?-terminal protein acetylation on protein (mis)folding and aggregation. No abstract available
  • ||||||||||  Journal:  Residential proximity to oil and gas developments and childhood cancer survival. (Pubmed Central) -  Jun 26, 2024   
    In neither case was HS truly present in this patient, but immunocytochemistry provided information that helped to optimize the patient's chemotherapy recommendations. Residential proximity to oil or gas wells at diagnosis is associated with the risk of mortality in children with AML or hepatoblastoma.
  • ||||||||||  Journal:  Case Series: Computed Tomography Features of Extraskeletal Osteosarcoma in Six Dogs. (Pubmed Central) -  Jun 26, 2024   
    Although the presence of intralesional mineralization is not a pathognomonic finding, it was consistently identified in the present case series. Therefore, exOSA should be considered in the differential diagnosis when mineralization occurs in a mass unrelated to osseous structures.
  • ||||||||||  Review, Journal:  Type II pleuropulmonary blastoma in a fetus: case report of a rare mesenchymal mediastinal tumor and literature review. (Pubmed Central) -  Jun 26, 2024   
    This case underscores the complexities of diagnosing fetal mediastinal tumors and contributes to the sparse literature on neonatal pleuropulmonary blastomas. Our comprehensive review of the differential diagnoses and literature emphasizes the unique characteristics of pleuropulmonary blastoma and its similarities to other soft tissue sarcomas, enhancing understanding of their clinical and genetic profiles.
  • ||||||||||  Review, Journal:  The role of O-GlcNAcylation in bone metabolic diseases. (Pubmed Central) -  Jun 25, 2024   
    However, the potential mechanisms by which O-GlcNAcylation regulates bone metabolism are not fully understood. In this paper, the literature related to the regulation of bone metabolism by O-GlcNAcylation was summarized to provide new potential therapeutic strategies for the treatment of orthopedic diseases such as arthritis and osteoporosis.
  • ||||||||||  Journal:  Dual targeting of KDM1A and antioxidants is an effective anticancer strategy. (Pubmed Central) -  Jun 25, 2024   
    We also show that KDM1A-specific inhibitor bizine synergized with antioxidant-depleting therapies, buthionine sulfoximine, and auranofin in rhabdomyosarcoma cell lines (Rh28 and Rh30). In this study, we describe a novel role for KDM1A in regulating HIF- 1A functions under oxidative stress and found that dual targeting of KDM1A and antioxidant systems may serve as an effective combination anticancer strategy.
  • ||||||||||  Review, Journal:  Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies. (Pubmed Central) -  Jun 25, 2024   
    Additionally, it underscores the imperative for subsequent research to further investigate the intricate interactions between the tumor microenvironment and the immune system, aiming to devise more effective treatment strategies. The present review comprehensively addresses the landscape of osteosarcoma immunotherapy, delineating crucial scientific concerns and clinical challenges, thereby outlining potential research directions.
  • ||||||||||  Review, Journal:  Prevalence of childhood cancer survivors in Europe: a scoping review. (Pubmed Central) -  Jun 25, 2024   
    The large variations in LDP and CP estimates were linked to differences in data availability, the selection of populations, prevalence measure, statistical method, incidence period, index date, age at diagnosis and prevalence, cancer types, sex, and, for LDP, also the length of follow-up. Standardisation of methodology and reporting are needed to systematically monitor and compare CCS prevalence in Europe and provide data to help address survivors' needs.
  • ||||||||||  bezuclastinib (PLX9486) / Cogent Biosci
    Enrollment open, Combination therapy, Monotherapy:  SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST (clinicaltrials.gov) -  Jun 25, 2024   
    P2,  N=40, Recruiting, 
    As opposed to other small bowel neoplasms, surgical resection with negative margins is the only potentially curative option. Not yet recruiting --> Recruiting
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Imfinzi (durvalumab) / AstraZeneca, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date, Combination therapy, Checkpoint inhibition, Metastases:  Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors (clinicaltrials.gov) -  Jun 25, 2024   
    P1/2,  N=100, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Oct 2025 --> Oct 2035 | Trial primary completion date: Oct 2024 --> Oct 2029